Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, combined with a immunopotentiator, LC9018, in mycobacterium intracellulare infection induced in beige mice.
スポンサーリンク
概要
- 論文の詳細を見る
A study was performed on the therapeutic efficacy of KRM-1648 combined with LC9018 in beige mice infected with Mycobacterium intracellulare. Each mouse was intravenously infected with 3.9×10<SUP>6</SUP>CFU, and then given 0.2mg of KRM-1648 emulsified in 2.5% gum arabic-0.2% Tween 80 by gavage once a day, six times per week, beginning 24h after infection for up to eight weeks. A sc injection of 0.1mg LC9018 in saline was given once or twice per week, beginning two weeks before infection to the end of experiment. An evaluation of the therapeutic efficacy of these drugs against the infection was performed on the basis of incidence and degree of gross lung lesions and bacterial loads in the lungs and spleen. Lung lesions were not observed in all experimental groups at four weeks after infection. However, at eight weeks after infection, although lung lesions were observed in all experimental groups, the degree of lesions was much milder in those mice receiving KRM-1 648 than in the control mice. The degree of lesions in the mice receiving LC9018 was much the same as that in the control mice. Moreover, the degree of lung lesions in mice treated with a combination of KRM-1648 and LC9018 was more severe than in those mice treated with KRM-1648 alone. The CFUs of organisms in the lungs and spleen of the mice treated with KRM-1648 were considerably lower than those of the control mice (P<0.05), but the CFUs in the mice treated with KRM-1648 and LC9018 were nearly the same as those mice treated with KRM-1648.
- 一般社団法人 日本結核病学会の論文
一般社団法人 日本結核病学会 | 論文
- 秋田県龜田町の結核実態調査-2-
- 秋田県龜田町の結核実態調査-1-
- 非定型抗酸菌排出者の臨床
- 正常人T細胞のE-rosette形成能に及ぼす肺結核患者血清の抑制作用
- 結核病巣内のmononuclear phagocytesの酵素活性,特にβ-galactosidaseおよびnaphthol AS-D acetate esteraseの変動